{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:14:00Z","timestamp":1791296040675,"version":"4.1.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are indicators of nutritional status in cancer patients; however, the effects of baseline mGPS and PNI on the duration of administration of the ghrelin receptor agonist anamorelin, which is used to treat cachexia in patients with cancer, are unclear. This study aimed to clarify the association of mGPS and PNI with the duration of oral anamorelin administration for patients who did not have beneficial effects from anamorelin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The attending physician determined the duration of oral anamorelin administration based on discontinuation due to cancer progression, poor efficacy, adverse events, or death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 12-week continuation rate of oral anamorelin was 30.4%. Univariate analysis revealed that an Eastern Cooperative Oncology Group performance status (ECOG-PS) of \u22652 (P\u00a0&amp;lt;\u00a0.001), concurrent chemotherapy (P\u00a0=\u00a0.002), albumin level (P\u00a0=\u00a0.005), C-reactive protein level (P\u00a0=\u00a0.013), and a mGPS of 2 (P\u00a0=\u00a0.014) were statistically significant predictors of the 12-week continuation rate of oral anamorelin. In the multivariate analysis, a mGPS of 2 remained a significant risk factor, and the ECOG-PS and concurrent chemotherapy had no effect on the association between the mGPS and 12-week continuation rate of oral anamorelin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with a mGPS of 2, compared with mGPS of 0 or 1, are less likely to maintain oral anamorelin therapy, regardless of the ECOG-PS or concurrent chemotherapy. Therefore, it is necessary to consider initiating anamorelin administration at mGPS 0 or 1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyae086","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T14:34:24Z","timestamp":1718634864000},"page":"1165-1170","source":"Crossref","is-referenced-by-count":4,"title":["Association of the modified Glasgow prognostic score and prognostic nutritional index with duration of oral anamorelin administration in patients with cancer cachexia: a retrospective cohort study"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-9164","authenticated-orcid":false,"given":"Kazuma","family":"Fujita","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital , Akita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Akamine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital , Akita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital , Akita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Fukushi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital , Akita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital , Akita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Akita University , Akita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Akita University Hospital , Akita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-3506","authenticated-orcid":false,"given":"Hiroyuki","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Akita University , Akita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"key":"2024110408211629100_ref1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2014.56.1894","article-title":"Diagnostic criteria for the classification of cancer-associated weight loss","volume":"33","author":"Martin","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024110408211629100_ref2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"2024110408211629100_ref3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"Argil\u00e9s","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2024110408211629100_ref4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.14.14","article-title":"Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome","volume":"10","author":"Currow","year":"2014","journal-title":"Future Oncol"},{"key":"2024110408211629100_ref5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1517\/14656566.2015.1041500","article-title":"Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC","volume":"16","author":"Zhang","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2024110408211629100_ref6","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"124","author":"Katakami","year":"2018","journal-title":"Cancer"},{"key":"2024110408211629100_ref7","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1002\/cncr.32406","article-title":"A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia","volume":"125","author":"Hamauchi","year":"2019","journal-title":"Cancer"},{"key":"2024110408211629100_ref8","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","article-title":"Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer","volume":"89","author":"Forrest","year":"2003","journal-title":"Br J Cancer"},{"key":"2024110408211629100_ref9","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jso.21154","article-title":"Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer","volume":"98","author":"Koike","year":"2008","journal-title":"J Surg Oncol"},{"key":"2024110408211629100_ref10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/etm.2010.175","article-title":"Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer","volume":"2","author":"Toiyama","year":"2011","journal-title":"Exp Ther Med"},{"key":"2024110408211629100_ref11","first-page":"1001","article-title":"Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients (in Japanese)","volume":"85","author":"Onodera","year":"1984","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"2024110408211629100_ref12","volume-title":"Adlumiz tabletsR [package insert on the internet]","author":"ONO PHARMACEUTICAL CO., LTD","year":"2023"},{"key":"2024110408211629100_ref13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.resinv.2022.10.003","article-title":"Prognostic role of modified Glasgow prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies","volume":"61","author":"Tanaka","year":"2023","journal-title":"Respir Investig"},{"key":"2024110408211629100_ref14","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.clgc.2020.10.007","article-title":"Modified Glasgow prognostic score as a predictor of prognosis in metastatic renal cell carcinoma treated with Nivolumab","volume":"19","author":"Fujiwara","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"2024110408211629100_ref15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12935-020-01558-4","article-title":"The prognostic value of modified Glasgow prognostic score in pancreatic cancer: a meta-analysis","volume":"20","author":"Zhang","year":"2020","journal-title":"Cancer Cell Int"},{"key":"2024110408211629100_ref16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/01635581.2020.1749290","article-title":"Modified Glasgow prognostic score, prognostic nutritional index and ECOG performance score predicts survival better than sarcopenia, cachexia and some inflammatory indices in metastatic gastric cancer","volume":"73","author":"Demirelli","year":"2021","journal-title":"Nutr Cancer"},{"key":"2024110408211629100_ref17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00520-023-08097-4","article-title":"Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia","volume":"31","author":"Tsukiyama","year":"2023","journal-title":"Support Care Cancer"},{"key":"2024110408211629100_ref18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3892\/ol.2023.14154","article-title":"Predictors of efficacy of anamorelin in patients with non-small cell lung cancer and cachexia: a retrospective study","volume":"27","author":"Ishioka","year":"2023","journal-title":"Oncol Lett"},{"key":"2024110408211629100_ref19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00520-023-07576-y","article-title":"Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study","volume":"31","author":"Iwai","year":"2023","journal-title":"Support Care Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/11\/1165\/60343180\/hyae086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/11\/1165\/60343180\/hyae086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T03:23:35Z","timestamp":1730690615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/11\/1165\/7701628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6,29]]},"published-print":{"date-parts":[[2024,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae086","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,6,29]]}}}